{"id":"NCT01994889","sponsor":"Pfizer","briefTitle":"Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy","officialTitle":"A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-09","primaryCompletion":"2018-02-07","completion":"2018-02-07","firstPosted":"2013-11-26","resultsPosted":"2019-04-03","lastUpdate":"2019-04-24"},"enrollment":441,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Transthyretin (TTR) Amyloid Cardiomyopathy"],"interventions":[{"type":"DRUG","name":"Tafamidis","otherNames":[]},{"type":"DRUG","name":"Tafamidis","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tafamidis - 20 mg","type":"EXPERIMENTAL"},{"label":"Tafamidis - 80 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.","primaryOutcome":{"measure":"Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations","timeFrame":"Baseline up to Month 30","effectByArm":[{"arm":"Tafamidis","deltaMin":8595,"sd":null},{"arm":"Placebo","deltaMin":5071,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":80,"countries":["United States","Belgium","Brazil","Canada","Czechia","France","Germany","Italy","Japan","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["40488446","39258729","39239341","38939456","38932583","38774010","37966817","37943223","37434378","36780092","36723935","36715498","36399070","36348245","35353352","35297655","34923848","34779246","33895806","33770392","33667442","33309574","33220323","33070419","32524297","30145929","28611125"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461028&StudyName=Safety%20and%20Efficacy%20of%20Tafamidis%20in%20Patients%20with%20Transthyretin%20Cardiomyopathy"]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":88},"commonTop":["Fall","Dyspnoea","Fatigue","Oedema peripheral","Dizziness"]}}